Cycle Announces the Appointment of Angela Kurtz as Clinical Metabolic Director to lead its newly created Clinical Metabolic Department

By |2021-05-17T18:52:30+01:00December 2nd, 2020|Generics, News|

Cycle Pharmaceuticals’ NITYR® (nitisinone) Tablets Receives Marketing Authorization in Israel

By |2021-05-17T18:52:30+01:00October 19th, 2020|News, Nityr|

US FDA Grants Once Daily Dosing Option For NITYR (nitisinone) Tablets for HT-1 Patients

By |2021-05-17T18:52:30+01:00September 14th, 2020|Generics, News|

Dr David Buckeridge Joins Cycle Group Holdings’ Board of Directors

By |2021-05-17T18:52:31+01:00September 8th, 2020|Generics, News|

Cycle Pharmaceuticals Features in the Sunday Times Tech Track Ones to Watch 2020

By |2021-05-17T18:52:31+01:00September 8th, 2020|Generics, News|

Cycle Pharmaceuticals Secures $25 Million Debt Financing

By |2021-05-17T18:52:31+01:00September 5th, 2020|Generics, News|

Cycle Launches COVID-19 Response For Eligible Patients with Tyrosinemia Type 1 (HT-1)

By |2021-05-17T18:52:31+01:00August 5th, 2020|News, Nityr|

Cycle Pharmaceuticals’ NITYR® (nitisinone) Tablets Receives Marketing Authorization in the Kingdom of Saudi Arabia

By |2021-05-17T18:52:31+01:00May 13th, 2020|News, Nityr|

Cycle Pharmaceuticals and Medherant Partner to Develop Medicines using the TEPI Patch® Technology

By |2021-05-17T18:52:31+01:00May 5th, 2020|News, Nityr|

Cycle Pharmaceuticals Launches New Informative Online Meeting Series for Patients With Tyrosinemia Type 1 in the US

By |2021-05-17T18:52:31+01:00April 19th, 2020|News, Resource|
Go to Top